Nanovibronix (NASDAQ:NAOV) is a medical technology company that develops and markets noninvasive, wearable ultrasound devices for therapeutic applications. The company’s core focus lies in wound management and pain relief using its proprietary ultrasonic platform, which delivers low-intensity acoustic energy through lightweight, disposable transducers. Nanovibronix’s products are designed to accelerate tissue repair, reduce inflammation and minimize reliance on pharmaceuticals in both acute and chronic care settings.
The company’s flagship offerings include the Dermacare System for chronic wound therapy and the PainShield System for postoperative pain management. Both systems have received regulatory clearances in multiple jurisdictions, including FDA 510(k) clearance in the United States and CE marking in the European Union. These approvals enable Nanovibronix to address a range of clinical needs, from diabetic foot ulcers and venous leg ulcers to postoperative orthopedic and soft tissue pain.
Founded in 2000 and headquartered in Danvers, Massachusetts, Nanovibronix maintains research and development operations in Israel, leveraging its cross-continental expertise in acoustics and medical device engineering. Over the years, the company has forged partnerships with hospitals, wound care centers and home health providers to integrate its ultrasound therapies into standard treatment protocols.
Led by a management team experienced in medical devices and regulatory affairs, Nanovibronix continues to expand its global footprint. The company markets its devices across North America, Europe, Israel and select Asian markets, aiming to broaden access to non-drug therapeutic options and improve patient outcomes in wound healing and pain management.
